GlassScriptPhysician profile
James V Linnick
NPI 1417961988
$5,873.64
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,128 · 2020: $1,191 · 2021: $1,537 · 2022: $1,483 · 2023: $498 · 2024: $35.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $533.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $533.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $875.59 | 2019-2023 | Farxiga, Fasenra, Breztri |
| Lilly USA, LLC | $646.49 | 2019-2023 | Mounjaro, Trulicity |
| Abbvie INC. | $603.90 | 2021-2023 | |
| Pfizer INC. | $508.73 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $500.41 | 2019-2023 | Stiolto Respimat, Spiriva Respimat |
| Novo Nordisk INC | $422.57 | 2019-2022 | |
| Glaxosmithkline, LLC. | $374.12 | 2019-2023 | Trelegy Ellipta |
| Vanda Pharmaceuticals INC. | $295.93 | 2020-2023 | Hetlioz |
| Abbott Laboratories | $243.32 | 2021-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Astellas Pharma US INC | $184.91 | 2019-2023 | Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $173.80 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $133.52 | 2020-2023 | Steglatro, Belsomra |
| Biohaven Pharmaceutical Holding Company LTD. | $119.75 | 2022 | |
| Eisai INC. | $111.70 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $107.86 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $101.13 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.07 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.03 | 2022 | |
| Philips North America LLC | $49.90 | 2021-2024 | (9520) Igt Devices Undivided |
| Mylan Specialty L.P. | $48.13 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $37.66 | 2019 | |
| Esperion Therapeutics, INC. | $33.62 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $33.46 | 2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $26.56 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $24.73 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $22.92 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $21.63 | 2019 | |
| Exact Sciences Corporation | $12.97 | 2023 | Cologuard Collection Kit |
| Genentech USA, INC. | $12.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Linnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.